Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2−) breast cancers?
暂无分享,去创建一个
[1] A. Børresen-Dale,et al. Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.
[2] J. Baselga,et al. A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. , 2012 .
[3] E. Winer,et al. SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC). , 2012 .
[4] C. Sotiriou,et al. Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial. , 2012 .
[5] J. Tabernero,et al. A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. , 2012 .
[6] N. Gray,et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. , 2012, Cancer discovery.
[7] Charles Swanton,et al. Intratumor Heterogeneity: Seeing the Wood for the Trees , 2012, Science Translational Medicine.
[8] Razelle Kurzrock,et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Nicholas T. Ingolia,et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis , 2012, Nature.
[10] Rosette Lidereau,et al. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups , 2012, Breast Cancer Research.
[11] M. Piccart,et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.
[12] Jordi Rodon,et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Ben Tran,et al. Luminal-B breast cancer and novel therapeutic targets , 2011, Breast Cancer Research.
[14] J. Balko,et al. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Ignatiadis,et al. Minimal residual disease and circulating tumor cells in breast cancer , 2011, Breast Cancer Research.
[16] Sydney L. Stoops,et al. Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape , 2011, Expert opinion on therapeutic patents.
[17] G. Mills,et al. PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer , 2011, Molecular Cancer Therapeutics.
[18] Rachel Schiff,et al. Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.
[19] T. Delozier,et al. Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI). , 2010 .
[20] J. Barrett,et al. PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer , 2010, Clinical Cancer Research.
[21] D. Carrasco,et al. PIK3CA mutations in in situ and invasive breast carcinomas. , 2010, Cancer research.
[22] G. Mills,et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. , 2010, The Journal of clinical investigation.
[23] Adrian V. Lee,et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer , 2010, Breast Cancer Research.
[24] Paul Ellis,et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer , 2010, Proceedings of the National Academy of Sciences.
[25] M. Belvin,et al. Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models , 2010, Clinical Cancer Research.
[26] J. Dancey. mTOR signaling and drug development in cancer , 2010, Nature Reviews Clinical Oncology.
[27] Hong Wang,et al. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. , 2010, Experimental and molecular pathology.
[28] M. Ranson,et al. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer , 2010, Breast Cancer Research and Treatment.
[29] J. Bartlett,et al. Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH , 2010, Histopathology.
[30] H. Lane,et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells , 2009, Proceedings of the National Academy of Sciences.
[31] Philippe P Roux,et al. mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling , 2009, Molecular and Cellular Biology.
[32] Robert L. Sutherland,et al. Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.
[33] W. Gerald,et al. PIK3CA Mutation Associates with Improved Outcome in Breast Cancer , 2009, Clinical Cancer Research.
[34] P. Pandolfi,et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. , 2009, Cancer cell.
[35] W. Yung,et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas , 2009, Molecular Cancer Therapeutics.
[36] R. Greil,et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] G. Mills,et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. , 2009, Cancer research.
[38] J. Olson,et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. , 2009, Cancer research.
[39] Funda Meric-Bernstam,et al. Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M. Holz,et al. S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation* , 2009, Journal of Biological Chemistry.
[41] J. Blenis,et al. Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy , 2009, Cell cycle.
[42] H. Seow,et al. PIK3CA gene mutations in breast carcinoma in Malaysian patients. , 2008, Cancer genetics and cytogenetics.
[43] A. Marchetti,et al. AKT1E17K in human solid tumours , 2008, Oncogene.
[44] L. Zhao,et al. Class I PI3K in oncogenic cellular transformation , 2008, Oncogene.
[45] Alice T. Loo,et al. PTEN-deficient cancers depend on PIK3CB , 2008, Proceedings of the National Academy of Sciences.
[46] P. Pandolfi,et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.
[47] Hans E. Huber,et al. Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling , 2008, PloS one.
[48] Zhi Hu,et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.
[49] S. Fox,et al. Down-Regulation of Phosphatidylinositol 3′-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer , 2008, Clinical Cancer Research.
[50] S. H. Lee,et al. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias , 2008, British Journal of Cancer.
[51] R. Schiff,et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.
[52] Rachel Schiff,et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. , 2008, Endocrine reviews.
[53] C. Tzen,et al. PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients , 2008, Annals of Surgical Oncology.
[54] G. Mills,et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.
[55] A. Marchetti,et al. Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas , 2007, Clinical Cancer Research.
[56] G. Mills,et al. A new mutational AKTivation in the PI3K pathway. , 2007, Cancer cell.
[57] M. Beeram,et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[58] Spyro Mousses,et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.
[59] Lewis C. Cantley,et al. AKT/PKB Signaling: Navigating Downstream , 2007, Cell.
[60] L. Skoog,et al. PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer , 2007, Clinical Cancer Research.
[61] M. Ringnér,et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.
[62] E. Tokunaga,et al. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma , 2007, Breast Cancer Research and Treatment.
[63] M. Monden,et al. Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women , 2007, Clinical Cancer Research.
[64] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[65] A. Lykkesfeldt,et al. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. , 2006, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[66] B. Iacopetta,et al. PIK3CA mutations in breast cancer are associated with poor outcome , 2006, Breast Cancer Research and Treatment.
[67] M. Hall,et al. TOR Signaling in Growth and Metabolism , 2006, Cell.
[68] D. Whyte,et al. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. , 2006, Biochemical and biophysical research communications.
[69] A. Marchetti,et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma , 2006, The Journal of pathology.
[70] M. Loda,et al. The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells , 2005 .
[71] J. Engelman,et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. , 2005, Cancer research.
[72] Wolfgang Eiermann,et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] Shiuan Chen,et al. Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer , 2005, Clinical Cancer Research.
[74] Carlo Rago,et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.
[75] J. Baselga,et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer , 2005 .
[76] Xin Huang,et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer , 2005, Breast Cancer Research.
[77] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[78] A. Lash,et al. Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers , 2005, Clinical Cancer Research.
[79] Rachel Schiff,et al. Estrogen-receptor biology: continuing progress and therapeutic implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] Manuel Hidalgo,et al. Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity , 2004, Clinical Cancer Research.
[81] Mariano Provencio,et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer , 2004, Genes, chromosomes & cancer.
[82] D. Guertin,et al. Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.
[83] I. Gout,et al. The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.
[84] Hiroyuki Konishi,et al. The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.
[85] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[86] Jiang Shou,et al. Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.
[87] Pier Paolo Pandolfi,et al. PTEN and p53: who will get the upper hand? , 2003, Cancer cell.
[88] D. Sabatini,et al. mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.
[89] Lewis C Cantley,et al. The phosphoinositide 3-kinase pathway. , 2002, Science.
[90] J E Paciga,et al. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. , 2001, Cancer research.
[91] Simak Ali,et al. Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.
[92] S Matsuno,et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. , 2000, Cancer research.
[93] Mariano Provencio,et al. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype , 1999, Breast Cancer Research and Treatment.
[94] A. Meindl,et al. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas , 1999, British Journal of Cancer.
[95] H. Feilotter,et al. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma , 1999, British Journal of Cancer.
[96] F. McCormick,et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. , 1998, Science.
[97] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[98] J. Cheng,et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.
[99] T. Pawson,et al. SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.
[100] G. Mills,et al. PI 3 K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer , 2011 .
[101] J. Olson,et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer , 2009, Breast Cancer Research and Treatment.
[102] G. Mills,et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. , 2009, Cancer research.
[103] L. Saal,et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair , 2008, Nature Genetics.
[104] C. Sotiriou,et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. , 2008, European journal of cancer.